Cogent Biosciences 3Q 2026: EPS ($0.59) — 10-Q Summary

Cogent Biosciences reported a larger quarterly net loss than a year earlier, as higher research and development spending and commercial-readiness investments lifted operating expenses. Increased interest income partially offset the expense growth.Financial Highlights² Reported as “Net loss”. ³ Repo…